Skip links
Orsini is the Exclusive Specialty Pharmacy for Cell Therapy ENCELTO™, for the Treatment of MacTel. Learn more →
Prescribe a Therapy
Orsini

← Back to Centers of Excellence

Nephrology Center of Excellence

Supporting patients living with a rare nephrology condition

Orsini’s Nephrology Center of Excellence launched in 2020 with our first program for primary hyperoxaluria type 1. Today we support multiple nephrology programs across several rare conditions. Our dedicated Therapy Care Teams work with the physician’s office and insurance on a patient’s behalf so that our patients and their family have more time to focus on their treatment and quality of life. We are here to listen, provide counseling on treatment, including side-effect management, and assist with sourcing third-party financial assistance.

Explore Our Nephrology Therapies

Benefits

Improving the Patient Experience, Every Time

Dedicated Care Team

Receive personalized support from a dedicated Therapy Care Team, including a primary pharmacy contact, clinical education, side-effects management, and scheduled refill calls.

Home Health Nursing

Access nationwide nursing support for in-home treatment or self-administration training. Our nurses provide clinical support to help patients achieve their treatment goals.

Insurance Coverage

Secure treatment coverage with assistance navigating payor and plan requirements. Our team proactively works with prescribers to obtain prior authorization and support appeals.

Free Care Overnight Shipping

Ensure medication and essential medical supplies arrive when and where patients need them through coordination across prescribers, patients, and care teams to arrange free overnight shipping.

Financial Assistance

Minimize financial exposure through financial assistance programs. We successfully identify and assist in enrolling patients into manufacturer co-pay and foundation support programs.

24/7/365 Access to a Pharmacist

Gain continuous access to a pharmacist, 24/7/365, ensuring ongoing care and clinical support for patients and prescribers to achieve better outcomes.

Support

Nephrology Conditions Supported

Explore the rare nephrology conditions and therapies Orsini supports below.

About Chronic Kidney Disease (CKD)

Chronic kidney disease (CKD) is a long-term condition in which a patient’s kidneys gradually lose function over time. It can lead to a buildup of waste and fluid in the body, causing complications like high blood pressure, anemia, weak bones, and heart disease. It’s commonly caused by diabetes or high blood pressure and can progress to kidney failure without treatment.

CKD Therapies Supported

Full Name FUROSCIX® (furosemide injection) 80 mg/10 mL for subcutaneous use
Drug Furosemide
Manufacturer scPharmaceuticals Inc.
Route of Administration Subcutaneous
Site of Care Home
Approved Indication FUROSCIX is indicated for the treatment of edema in adult patients with chronic heart failure or chronic kidney disease, including the nephrotic syndrome. Please see the full Prescribing Information and Instructions for Use.
Disease Chronic heart Failure; Chronic kidney disease
Therapeutic Area Cardiology; Nephrology
Enrollment Form Link www.furoscix.com/hcp/contact-us
Phone Number 855-387-6724
Product Website www.furoscix.com/hcp/

About Fabry disease

Fabry disease belongs to a group of diseases known as lysosomal storage disorders. It is a rare inherited disorder of lipid (fat) metabolism which results from the deficient activity of the enzyme, alpha-galactosidase A (a-Gal A). This leads to a buildup of a particular type of fat in the body’s cells, called globotriaosylceramide or GL-3, that affects many parts of the body. Signs and symptoms may include episodes of pain, particularly in the hands and feet, clusters of small, dark red spots on the skin, a decreased ability to sweat, cloudiness of the front part of the eye and hearing loss. Complications such as progressive kidney damage, heart attack, and stroke can be life-threatening.

Fabry Disease Therapies Supported

Full Name Elfabrio® (pegunigalsidase alfa-iwxj)
Drug Elfabrio
Manufacturer Chiesi
Route of Administration Intravenous
Site of Care Home or Healthcare Facility
Approved Indication The treatment of adults with confirmed Fabry disease
Disease Fabry disease
Therapeutic Area Neurology, Nephrology, Genetics
Enrollment Form Link Enrollment Form
Phone Number 833-656-1056
Fax Number 636-355-3610
Product Website hcp.elfabrio.com

Full Name Fabrazyme® (agalsidase beta)
Drug Fabrazyme
Manufacturer Sanofi Genzyme
Route of Administration Intravenous
Site of Care Home or Healthcare Facility
Approved Indication The treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease
Disease Fabry disease
Therapeutic Area Neurology, Nephrology, Genetics
Enrollment Form Link Enrollment Form
Phone Number 800-240-9572
Fax Number 877-220-7581
Product Website hcp.fabrazyme.com

About Homozygous Cystinuria

Homozygous cystinuria is a rare genetic disorder characterized by the presence of two identical mutations in the genes responsible for cystine transport in the kidneys. This results in impaired reabsorption of cystine, leading to its excessive accumulation in the urine. Cystine forms crystals that can combine to create kidney stones, causing recurrent and often painful episodes of nephrolithiasis. Individuals with homozygous cystinuria face an increased risk of kidney damage and related complications.

Homozygous Cystinuria Therapies Supported

Full Name tiopronin
Drug Tiopronin
Manufacturer Generic
Route of Administration Oral
Site of Care Home
Approved Indication In combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 9 years of age and older with severe homozygous cystinuria, who are not responsive to these measures alone
Disease Homozygous Cystinuria
Therapeutic Area Nephrology
Enrollment Form Link Tiopronin Enrollment Form
Phone Number 800-764-0147
Fax Number 877-848-6579
Product Website

About Primary Hyperoxaluria Type 1 (PH1)

Primary Hyperoxaluria Type 1 is an ultra-rare genetic disease characterized by the overproduction of oxalate, a waste product that usually is eliminated by the kidneys and excreted in the urine. The excess production of oxalate results in the deposition of calcium oxalate crystals in the kidneys and urinary tract and can lead to the formation of painful and recurrent kidney stones, nephrocalcinosis, progression to kidney failure, and systemic organ dysfunction. It is estimated that PH1 affects one to three individuals per million in the United States and Europe.

PH1 Therapies Supported

Full Name Oxlumo® (lumasiran)
Drug Oxlumo
Manufacturer Alnylam Pharmaceuticals
Route of Administration Subcutaneous
Site of Care Home or Healthcare Facility
Approved Indication The treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients
Disease Primary Hyperoxaluria Type 1 (PH1)
Therapeutic Area Nephrology
Enrollment Form Link Oxlumo Enrollment Form
Phone Number 800-460-5217
Fax Number 877-276-8563
Product Website oxlumo.com

About Urea Cycle Disorders (UCDs)

Urea cycle disorders are a group of rare, genetic disorders that can cause harmful ammonia to build up in the blood, potentially resulting in brain damage and neurocognitive impairments if ammonia levels are not controlled. Any increase in ammonia over time is serious. Therefore, it is important to adhere to any dietary protein restrictions and have alternative medication options to help control ammonia levels.

UCD Therapies Supported

Full Name OLPRUVA® (sodium phenylbutyrate)
Drug Olpruva
Manufacturer Zevra Therapeutics, Inc.
Route of Administration Oral
Site of Care Home
Approved Indication Chronic management of adult and pediatric patients weighing 20 kg or greater and with a body surface area (BSA) of 1.2 m2 or greater, with urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS)
Disease Urea Cycle Disorders (UCDs)
Therapeutic Area Nephrology
Enrollment Form Link Enrollment Form
Phone Number 800-837-8905
Fax Number 877-369-3806
Product Website olpruvahcp.com